NIH Bioassay Research Database (BARD) AJIT JADHAV NIH/NCATS SEPTEMBER 25, 2013 Presentation Highlights • Introduction to NCATS ‘Open Source’ Drug Discovery  • Motivations for BARD • Interacting with BARD • Extensibility & Community The Best of Times, The Worst of Times Fundamental science unprecedentedly advanced, but: • Poor transition of basic or clinical observations into to interventions that tangibly improve human health • Drug/device/diagnostic development system in crisis • Clinical trials system in crisis • Poor adoption of demonstrably useful interventions People unhealthier and funders of biomedical research enterprise (public and private) impatient NCATS Mission To catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Catalyzing Collaborations Within NIH NCI NHLBI NIAID OD NIDCR NEI NIDA NIA CC NIAMS NIDDK NLM CIT FIC NCATS NHGRI NICHD NIEHS NINDS NIBIB NIAAA NIDCD NIMH CSR NCCAM NINR NIGMS NIMHD Catalyzing Collaborations Outside NIH • Complements ― does not compete ― with the work of Academia others Advocacy Biotech Groups • Revolutionizes the process of translation by promoting innovative research NCATS • Galvanizes and supports new partnerships Non- Pharma Profits • Supports and augments regulatory science and its application FDA • Expands the precompetitive space NCATS Programs and Initiatives Clinical and Translational Science Activities • Clinical and Translational Science Awards Rare Diseases Research and Therapeutics • Therapeutics for Rare and Neglected Diseases • Bridging Interventional Development Gaps • Office of Rare Diseases Research Re-engineering Translational Sciences • NIH Chemical Genomics Center • Toxicology in the 21st Century Creating a Human Genome Translation Toolbox Small molecules Transcriptome (MLP) cDNA collection (MGC) Reference Sets (MRT Project) siRNAs ENCyclopedia Of DNA Elements KO mice genome-wide (KOMP) The “Non-Druggable” Genome Problem Drug Target Classes Human Genome 46% Receptor (1543, 5%) (n=483) GPCRs Nuclear Receptors Enzymes Othe r Ion Channels Unknown Drews, J. (2000) Science 287:1962 Venter et al., (2001) Science 291:1304 Molecular Libraries Program Enabled by Convergent Developments Robotic HTOS Technology Human Compound Genome Libraries Project Assay Technology Availability of Availability of Availability of compounds targets screening, ADME “Open Source” Chemical Biology and Drug Discovery